Navigation Links
Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program
Date:10/14/2009

ost=http%3A%2F%2Fpowerlink%2Epowerstream%2Enet&w=349&h=400&clip=1&contID=MatrixTrial&bypass=">click here to view a television segment featuring an investigator in the study, Dr. Peter A. Blume of the Yale University School of Medicine, and click here to view a segment featuring Dr. Barbara Aung of the Aung Foothealth Clinics, and their patients enrolled in the Matrix clinical study. The Matrix study media segments can also be accessed at www.cardiumthx.com.

Matrix Phase 2b Clinical Study

The Matrix Phase 2b clinical study was a multi-center U.S.-based study designed to evaluate Excellarate for the potential treatment of non-healing diabetic foot ulcers. Enrollment in the study was ended early after key efficacy measures among blinded groups were observed at rates substantially higher than those expected for patients receiving only standard of care. The study, which was conducted at 20 medical centers, evaluated patients that were treated with the gene-activated Excellarate product candidate (Ad5PDGF-B / 2.6% collagen) or the collagen matrix component of Excellarate, compared to patients who received only standard of care treatment without any applied Ad5PDGF-B or collagen. A per protocol data analysis included 113 patients with lower extremity neuropathic ulcers that were chronically non-healing despite receiving standard of care. Eleven additional patients who were initially recruited into the trial were excluded (7 patients were lost to evaluation or had a disqualifying surgical procedure and 4 were determined to have been mis-enrolled based on prespecified enrollment criteria,
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers
2. Scientific Journal Gene Therapy Reports That Cardiums Gene Activated Matrix Technology Accelerates Periodontal Tissue Regeneration
3. Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments
4. Cardium Completes Sale of InnerCool Therapies Business to Royal Philips Electronics
5. Cardium Receives Preliminary Notification of Inclusion in the Russell 3000(R) Index and Russell Global(R) Index
6. Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting
7. Cardium Reports on First Quarter 2009 Financial Results and Recent Developments
8. Cardium Reports on New Excellarate(TM) Product Formulations to Expand Commercialization Potential Into Multiple Wound Healing Applications
9. Cardium Provides Update Regarding Exchange Listing Compliance Plan Accepted by NYSE Amex
10. Cardiums InnerCool Announces Journal of Neurotrauma Highlights Hypothermia Therapys Role in Post Cardiac Arrest, and Traumatic Brain and Spinal Cord Injury Patients
11. Cardium Reports on Recent Highlights, Financial Results and 2009 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... ... a Balloon Sinuplasty website to inform potential Nashville area sinus sufferers ... can be used to determine if someone is a good candidate for Balloon ...
(Date:7/30/2015)... ... July 31, 2015 , ... Reduce Human Error ... **Presented by FDAnews and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 – Raleigh, ... helping drug, biologic and device firms reduce manufacturing errors by 50 percent or ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... announces I am Fine, an app invention that can help people during emergencies. ... says Scott Cooper, CEO and Creative Director of World Patent Marketing. "Currently, there ...
(Date:7/30/2015)... ... July 30, 2015 , ... In an effort to provide the twenty ... making a change in his practice. , The decision will also allow him to ... Aggarwal will be transferring his in-patient admissions to the hospitalists at East Liverpool City ...
(Date:7/30/2015)... ... 30, 2015 , ... In a meaningful ritual intended to symbolize a final ... Center have created an addiction graveyard. Sharing this with the public comes at a ... Rocky Hudson . Hudson (1945-2015) fell in love with the desert when he moved ...
Breaking Medicine News(10 mins):Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3
... about memory could offer an early warning system for ... at Rush University Medical Center. The researchers have found// ... changes in the brain related to Alzheimer's disease. Their ... Neurology. ,The researchers looked at the association ...
... issued on Dec 1 (World AIDS Day), more than 3 ... to// HIV and million jobs a year are lost due ... crippling effect on the workforce of many countries. ... the future working generations – the report said. The ILO ...
... time of vaccination may reduce the effectiveness of the vaccine, ... the goal is to produce as many antibodies as possible ... ,To do this, white blood cells (B cells) that ... body against infections spring into action to produce the antibodies. ...
... that GPs earnings average around ?106,000 in the initial ... Centre for health and social care depict an increase ... 2004-05. ,Ministers and NHS Bigwigs are mighty ... instead of pumping them for improving the quality of ...
... in the news for the wrong reasons and now scientists ... agent of the side-//effects. The answer hovers around the vital ... scientists reveal., ,These drugs known as COX-2 inhibitors ... like arthritis. The drugs achieve its purpose by hampering the ...
... Canada has informed Swiss Pharmaceutical Roche AG to include ... influenza drug, Tami flu. This advice is close// on ... the drug, sparking erratic behaviors, hallucination and even inducing ... teens in Japan. , ,According to a statement ...
Cached Medicine News:Health News:Memory Complaints Are Associated With Alzheimer's Disease 2Health News:Memory Complaints Are Associated With Alzheimer's Disease 3Health News:ILO Reports On The Crippling Effects Of HIV On The Workforce 2
(Date:7/30/2015)... July 30, 2015   Sentrian , the ... preventable hospitalization, recently received confirmation from the Food ... Intelligence (RPI) solution meets the definition of a ... exercise "Enforcement Discretion." The designation ... further FDA regulatory requirements at this time" and ...
(Date:7/30/2015)... 30, 2015 What can be ... areas are going to grow at the fastest rates? ... revenues to 2025, assessing data, trends, opportunities and prospects ... 176 tables, charts, and graphs. Discover the most lucrative ... Our new study lets you assess forecasted sales at ...
(Date:7/30/2015)... Company, Inc. (NYSE: LCI ) today announced that ... Annual Growth Conference on Wednesday, August 12, 2015, at ... A webcast of the presentation will be ... visit the web site at least 10 minutes prior ... and install any necessary software.  The presentation will be ...
Breaking Medicine Technology:FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 2FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6
... Catalyst,Pharmaceutical Partners, Inc. (Nasdaq: CPRX ... develops and commercializes prescription,drugs for the treatment ... announced that it has begun enrollment for ... trial evaluating,CPP-109 for the treatment of patients ...
... Company,s End-of-Phase II Meeting with FDA Set for ... TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ) today ... Meeting of the American Headache Society showed that, ... pain relief at two,hours, the company,s lead AMPA/kainate-type ...
Cached Medicine Technology:Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction 2Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction 3Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction 4Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel 2Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel 3
... Continuing a tradition of progressive centrifuge ... CL3 series. The Centra-CL3 and Centra-CL3R (refrigerated) ... todays laboratory., Quality Control Over Sample ... and lock up to 99 protocols and ...
Inquire...
... Rotor has a standard 1.5ml rotor and 6 ... Easy operation (no switches to mess with). Simply ... the plastic tab to open. Starts and stops ... 2000 x g. Only five inches in diameter. ...
Inquire...
Medicine Products: